• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·603939.SS
Share

Yifeng Pharmacy Chain Co., Ltd. Stocks

CN¥ 25.75Last Updated 26.10.2026

Issuer Rating

5/7
Performance

Favourable

Risk

Moderate

Recommendation

Hold

Market Cap

CN¥ 4.61B

CN¥ 25.75
Key Takeaways

Risk factor

Very vulnerable to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Yifeng Pharmacy Chain Co., Ltd. serves as a key distributor of pharmaceutical goods across China. As of March 31, 2021, the company oversaw an expansive network of approximately 6,279 retail pharmacies. These establishments are strategically situated throughout various significant Chinese provinces and municipalities, including Hunan, Hubei, Shanghai, Jiangsu, Zhejiang, Jiangxi, Guangdong, Hebei, and Beijing. The firm was founded in 2001 and has its primary corporate office located in Changsha, China.

Company Valuation

Slightly undervalued
5/7

Considering past and projected metrics, the stock is slightly 'cheaper' than its peers. Specifically, the stock is fairly valued on P/E, undervalued on EV/EBITDA, underpr

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of 603939.SS is 32.0 and suggests 26.3% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

27.10.2026 01:51

Anthropic Disclosed Its Reliance on Google, Amazon, and Microsoft Ahead of Its IPO. What Is the Risk?

27.10.2026 00:38

Microsoft is cutting costs: 60,000 employees have been offered voluntary separation

27.10.2026 00:18

"If the bubble bursts, it will all start with debt": How the problems of the neo-claws threaten the S&P 500

26.10.2026 23:40

Buyers of the foldable iPhone have complained about screen damage. How does this affect the stock price?

26.10.2026 23:02

One of Wall Street’s biggest bulls drops overweight call on stocks ahead of midterms

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026